Beyond Air will report Q3 financial results on February 13, 2026, followed by a conference call at 8:00 AM ET.
Quiver AI Summary
Beyond Air, Inc. announced its financial results for the third fiscal quarter ending December 31, 2025, will be reported on February 13, 2026. The company will host a conference call and webcast at 8:00 am Eastern Time that day, with details available for participants to join. Beyond Air is focused on using nitric oxide in its medical devices and biopharmaceuticals to treat patients with respiratory illnesses, neurological disorders, and solid tumors. The company has FDA approval and CE Mark for its LungFit PH system, which treats hypoxic respiratory failure in neonates, and is conducting clinical trials on other LungFit systems for severe lung infections. Beyond Cancer, Ltd., an affiliate of Beyond Air, is also researching ultra-high concentrations of nitric oxide for solid tumor treatment in pre-clinical settings.
Potential Positives
- Beyond Air is set to report its financial results for the third fiscal quarter, providing transparency to investors and stakeholders about the company's performance.
- The upcoming conference call and webcast offers an opportunity for direct engagement with company management, potentially strengthening investor relations.
- The FDA approval and CE Mark for LungFit PH indicates regulatory validation of Beyond Air's innovative technology for treating neonates with hypoxic respiratory failure.
- The company's focus on advancing clinical trials for treating severe lung infections and solid tumors demonstrates its commitment to addressing critical healthcare challenges.
Potential Negatives
- The company did not provide any financial guidance or expectations for the upcoming results, which may raise concerns among investors about transparency and performance.
- The absence of detailed information on ongoing clinical trials and their timelines could lead to skepticism regarding the progress and future prospects of the company’s pipeline.
- Publishing results on February 13, 2026, without prior announcement of supporting data may leave stakeholders questioning the financial viability and operational strategies of the company.
FAQ
When will Beyond Air report its financial results for Q3 2026?
Beyond Air will report its financial results for the third fiscal quarter on February 13, 2026.
How can I access the conference call for Beyond Air's Q3 financial results?
The conference call can be accessed by phone at 1-877-407-0784 for domestic calls and 1-201-689-8560 for international calls.
What is the purpose of Beyond Air's study on nitric oxide?
Beyond Air focuses on harnessing nitric oxide to improve treatment for patients with respiratory illnesses and neurological disorders.
What systems does Beyond Air currently have in clinical trials?
Beyond Air is advancing its LungFit systems to treat severe lung infections, including viral pneumonia and nontuberculous mycobacteria.
Who can I contact for more information about Beyond Air?
For more information, you can contact Corey Davis, Ph.D., at LifeSci Advisors via email at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XAIR Revenue
$XAIR had revenues of $1.8M in Q2 2026. This is an increase of 127.82% from the same period in the prior year.
You can track XAIR financials on Quiver Quantitative's XAIR stock page.
$XAIR Hedge Fund Activity
We have seen 15 institutional investors add shares of $XAIR stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. removed 2,870,248 shares (-86.1%) from their portfolio in Q3 2025, for an estimated $6,630,272
- KINGDON CAPITAL MANAGEMENT, L.L.C. removed 889,850 shares (-95.0%) from their portfolio in Q3 2025, for an estimated $2,055,553
- ALYESKA INVESTMENT GROUP, L.P. added 759,061 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,753,430
- BLEICHROEDER LP added 49,573 shares (+134.3%) to their portfolio in Q3 2025, for an estimated $114,513
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 44,306 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $102,346
- VANGUARD GROUP INC added 31,814 shares (+43.8%) to their portfolio in Q3 2025, for an estimated $73,490
- VIRTU FINANCIAL LLC added 20,881 shares (+inf%) to their portfolio in Q3 2025, for an estimated $48,235
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XAIR Analyst Ratings
Wall Street analysts have issued reports on $XAIR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 08/21/2025
To track analyst ratings and price targets for $XAIR, check out Quiver Quantitative's $XAIR forecast page.
Full Release
GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its third fiscal quarter ended December 31, 2025 on Friday, February 13, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time the same day.
|
Conference Call & Webcast
|
|
| Friday, February 13 th @ 8:00 AM ET | |
| Domestic: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: | 13758405 |
| Webcast: | A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website ( click here ) or directly ( click here ). An online replay will be available on the Company’s website or via the direct link an hour after the call. |
About Beyond Air, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net .
CONTACTS:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
[email protected]
(212) 915-2577
